Form 4: MoonLake Immunotherapeutics Director Spike Loy Acquires Options
SEC Form 4
Director Spike Loy acquired options to purchase 7,688 Class A Ordinary Shares in MoonLake Immunotherapeutics on June 6, 2024.
Summary
- On June 6, 2024, Spike Loy, a director of MoonLake Immunotherapeutics, acquired options to purchase 7,688 Class A Ordinary Shares.
- The exercise price of the options is $42.44.
- The options vest in full on the earlier of June 6, 2025, the date of the Issuer's next annual general meeting of shareholders, or the date of a Change in Control of the Issuer, subject to continued service.
- The options expire on June 6, 2034.
Sentiment
Score: 5
Explanation: The document is a routine regulatory filing, and there is no inherent positive or negative sentiment associated with it.
Industry Context
This is a standard Form 4 filing, reflecting a change in beneficial ownership by a company insider. Such filings are common and provide transparency to the market regarding insider transactions.
Stakeholder Impact
- The transaction provides transparency to shareholders regarding insider activity.
Key Dates
| Date | Description |
|---|---|
| 06/06/2024 | Date of transaction: Spike Loy acquired options to purchase 7,688 Class A Ordinary Shares. |
| 06/06/2025 | Earliest vesting date for the options, contingent on continued service. |
| 06/06/2034 | Expiration date of the options. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.